Human / Mouse / Rat Blood Vessels (CD31 / Von Willebrand Factor (vWF)) IHC staining Kit from CHEMICON
Description:CHEMICONs Blood Vessel Staining Kit is a very sensitive immunohistochemical tool for the detection of vascular endothelial cells, containing both anti-von Willebrand Factor and anti-CD31 primary antibodies and is applicable to a variety of species. This AP kit provides a simple, all-in-one method for the staining of frozen and paraffin-embedded sections in human (both CD31 and
vWF) or rat and mou...
Company:CHEMICON
STA VWF CALIBRATOR
Description:Citrated human plasma for the calibration of
vWF assays by the immuno-turbidimetric method on STA© analyzers.(STA© Liatest©
vWF #0518)....
Company:Diagnostica Stago, Inc.
ASSERACHROM vWF
Description:Enzyme Immunoassay of von Willebrand Factor Antigenby ELISA Method, 96 tests....
Company:Diagnostica Stago, Inc.
STA LIATEST VWF
Description:Immuno-turbidimetric Assay of von Willebrand Factor (
vWF) Antigen by STA© Analyzers. Microlatex particles coated with rabbit anti-human
vWF antibodies....
Company:Diagnostica Stago, Inc.
ADAMTS13 Activity & Inhibitor (VWF Cleaving Protease)
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
VWF Ag
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
Ablynx Announces Interim Results of First Nanobody Phase I Study of
ALX-0081 (ANTI-VWF)
GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positiveinterim results from the ongoing Phase I study of its leaddevelopment programme, ALX-0081, an anti-thrombotic treatment.ALX-0081 is a novel ´first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (
vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Pha...